Cargando…

Clinical challenges in interpreting multiple pathogenic mutations in single patients

BACKGROUND: In the past two decades, genetic testing for cancer risk assessment has entered mainstream clinical practice due to the availability of low-cost panels of multiple cancer-associated genes. However, the clinical value of multiple-gene panels for cancer susceptibility is not well establish...

Descripción completa

Detalles Bibliográficos
Autores principales: Slaught, Christa, Berry, Elizabeth G., Bacik, Lindsay, Skalet, Alison H., Anadiotis, George, Tuohy, Therese, Leachman, Sancy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863461/
https://www.ncbi.nlm.nih.gov/pubmed/33541411
http://dx.doi.org/10.1186/s13053-021-00172-3
_version_ 1783647499024596992
author Slaught, Christa
Berry, Elizabeth G.
Bacik, Lindsay
Skalet, Alison H.
Anadiotis, George
Tuohy, Therese
Leachman, Sancy A.
author_facet Slaught, Christa
Berry, Elizabeth G.
Bacik, Lindsay
Skalet, Alison H.
Anadiotis, George
Tuohy, Therese
Leachman, Sancy A.
author_sort Slaught, Christa
collection PubMed
description BACKGROUND: In the past two decades, genetic testing for cancer risk assessment has entered mainstream clinical practice due to the availability of low-cost panels of multiple cancer-associated genes. However, the clinical value of multiple-gene panels for cancer susceptibility is not well established, especially in cases where panel testing identifies more than one pathogenic variant. The risk for specific malignancies as a result of a mutated gene is complex and likely influenced by superimposed modifier variants and/or environmental effects. Recent data suggests that the combination of multiple pathogenic variants may be fewer than reported by chance, suggesting that some mutation combinations may be detrimental. Management of patients with “incidentally” discovered mutations can be particularly challenging, especially when established guidelines call for radical procedures (e.g. total gastrectomy in CDH1) in patients and families without a classic clinical history concerning for that cancer predisposition syndrome. CASE PRESENTATION: We present two cases, one of an individual and one of a family, with multiple pathogenic mutations detected by multi-gene panel testing to highlight challenges practitioners face in counseling patients about pathogenic variants and determining preventive and therapeutic interventions. CONCLUSIONS: Ongoing investigation is needed to improve our understanding of inherited susceptibility to disease in general and cancer predisposition syndromes, as this information has the potential to lead to the development of more precise and patient-specific counseling and surveillance strategies. The real-world adoption of new or improved technologies into clinical practice frequently requires medical decision-making in the absence of established understanding of gene-gene interactions. In the meantime, practitioners must be prepared to apply a rationale based on currently available knowledge to clinical decision-making. Current practice is evolving to rely heavily on clinical concordance with personal and family history in making specific therapeutic decisions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13053-021-00172-3.
format Online
Article
Text
id pubmed-7863461
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78634612021-02-05 Clinical challenges in interpreting multiple pathogenic mutations in single patients Slaught, Christa Berry, Elizabeth G. Bacik, Lindsay Skalet, Alison H. Anadiotis, George Tuohy, Therese Leachman, Sancy A. Hered Cancer Clin Pract Case Report BACKGROUND: In the past two decades, genetic testing for cancer risk assessment has entered mainstream clinical practice due to the availability of low-cost panels of multiple cancer-associated genes. However, the clinical value of multiple-gene panels for cancer susceptibility is not well established, especially in cases where panel testing identifies more than one pathogenic variant. The risk for specific malignancies as a result of a mutated gene is complex and likely influenced by superimposed modifier variants and/or environmental effects. Recent data suggests that the combination of multiple pathogenic variants may be fewer than reported by chance, suggesting that some mutation combinations may be detrimental. Management of patients with “incidentally” discovered mutations can be particularly challenging, especially when established guidelines call for radical procedures (e.g. total gastrectomy in CDH1) in patients and families without a classic clinical history concerning for that cancer predisposition syndrome. CASE PRESENTATION: We present two cases, one of an individual and one of a family, with multiple pathogenic mutations detected by multi-gene panel testing to highlight challenges practitioners face in counseling patients about pathogenic variants and determining preventive and therapeutic interventions. CONCLUSIONS: Ongoing investigation is needed to improve our understanding of inherited susceptibility to disease in general and cancer predisposition syndromes, as this information has the potential to lead to the development of more precise and patient-specific counseling and surveillance strategies. The real-world adoption of new or improved technologies into clinical practice frequently requires medical decision-making in the absence of established understanding of gene-gene interactions. In the meantime, practitioners must be prepared to apply a rationale based on currently available knowledge to clinical decision-making. Current practice is evolving to rely heavily on clinical concordance with personal and family history in making specific therapeutic decisions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13053-021-00172-3. BioMed Central 2021-02-04 /pmc/articles/PMC7863461/ /pubmed/33541411 http://dx.doi.org/10.1186/s13053-021-00172-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Slaught, Christa
Berry, Elizabeth G.
Bacik, Lindsay
Skalet, Alison H.
Anadiotis, George
Tuohy, Therese
Leachman, Sancy A.
Clinical challenges in interpreting multiple pathogenic mutations in single patients
title Clinical challenges in interpreting multiple pathogenic mutations in single patients
title_full Clinical challenges in interpreting multiple pathogenic mutations in single patients
title_fullStr Clinical challenges in interpreting multiple pathogenic mutations in single patients
title_full_unstemmed Clinical challenges in interpreting multiple pathogenic mutations in single patients
title_short Clinical challenges in interpreting multiple pathogenic mutations in single patients
title_sort clinical challenges in interpreting multiple pathogenic mutations in single patients
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863461/
https://www.ncbi.nlm.nih.gov/pubmed/33541411
http://dx.doi.org/10.1186/s13053-021-00172-3
work_keys_str_mv AT slaughtchrista clinicalchallengesininterpretingmultiplepathogenicmutationsinsinglepatients
AT berryelizabethg clinicalchallengesininterpretingmultiplepathogenicmutationsinsinglepatients
AT baciklindsay clinicalchallengesininterpretingmultiplepathogenicmutationsinsinglepatients
AT skaletalisonh clinicalchallengesininterpretingmultiplepathogenicmutationsinsinglepatients
AT anadiotisgeorge clinicalchallengesininterpretingmultiplepathogenicmutationsinsinglepatients
AT tuohytherese clinicalchallengesininterpretingmultiplepathogenicmutationsinsinglepatients
AT leachmansancya clinicalchallengesininterpretingmultiplepathogenicmutationsinsinglepatients